Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1425-1437

  Thomas, Shibu ^a   Muralidharan, A ^a   Shah, Girish V ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Calcitonin; Knock down; Receptor; Tumor growth

Indexed keywords

CALCITONIN RECEPTOR; UROKINASE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER INVASION; CELL PROLIFERATION; DRUG ANTAGONISM; GENETICS; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, CALCITONIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 38449116087     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1425     Document Type: Article

References (39)

1. Presti JC Jr: Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am 38: 49-58, 2000.
2. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
3. Furuya Y, Akakura K, Akimoto S, Inomiya H and Ito H: Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int J Urol 6: 240-244, 1999.
4. Segawa N, Mori I, Utsunomiya H, et al: Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 51: 452-459, 2001.
5. Vilches J, Salido M, Fernandez-Segura E and Roomans GM: Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments. Histol Histopathol 19: 951-961, 2004.
6. Tilley WD, Buchanan G, Hickey TE and Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277-285, 1996.
7. Miyake H, Nelson C, Rennie PS and Gleave ME: Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60: 2547-2554, 2000.
8. Kaibuchi T, Furuya Y, Akakura K, Masai M and Ito H: Changes in cell proliferation and apoptosis during local progression of prostate cancer. Anticancer Res 20: 1135-1139, 2000.
9. Howell SB: Resistance to apoptosis in prostate cancer cells. Mol Urol 4: 225-231, 2000.
10. Chien J, Ren Y, Qing Wang Y, et al: Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol 181: 69-79, 2001.
11. Thomas S, Chigurupati S, Anbalagan M and Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol 20: 1894-1911, 2006.
12. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
13. Shah GV, Rayford W, Noble MJ, et al: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmic Ca2+ transients. Endocrinology 134: 596-602, 1994.
14. Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG and Shah GV: Constitutive activation of stimulatory guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 18: 3376-3382, 1999.
15. Shah GV, Chien J, Sun YP, Puri S and Ravindra R: Calcitonin inhibits anterior pituitary cell proliferation in the adult female rats. Endocrinology 140: 4281-4291, 1999.
16. Sabbisetti VS, Chirugupati S, Thomas S, et al: Calcitonin increases invasiveness of prostate cancer cells: Role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer 117: 551-560, 2005.
17. Larran J, Salido M, Aparicio J, Lopez A, de Palacio ML and Vilches J: In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DU 145 and LNCaP cancer prostatic cell lines. Int J Dev Biol Suppl 1: 275S-276S, 1996.
18. Thomas S and Shah GV: Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther 4: 1226-1233, 2005.
19. Lim DJ, Liu XL, Sutkowski DM, Braun EJ, Lee C and Kozlowski JM: Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 22: 109-118, 1993.
20. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME and Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44: 3522-3529, 1984.
21. D'Alessio S, Margheri F, Pucci M, et al: Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 110: 125-133, 2004.
22. Arens N, Gandhari M, Bleyl U and Hildenbrand R: In vitro suppression of urokinase plasminogen activator in breast cancer cells - A comparison of two antisense strategies. Int J Oncol 26: 113-119, 2005.
23. Miyagishi M, Hayashi M and Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 13: 1-7, 2003.
24. Shukeir N, Pakneshan P, Chen G, Szyf M and Rabbani SA: Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res 66: 9202-9210, 2006.
25. Salvi A, Arici B, De Petro G and Barlati S: Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 3: 671-678, 2004.
26. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M and Rao JS: Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 1: 165-176, 2004.
27. Jiang M, Rubbi CP and Milner J: Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides 14: 239-248, 2004.
28. Alemany R, Gomez-Manzano C, Balague C, et al: Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252: 1-12, 1999.
29. van Beusechem VW, Grill J, Mastenbroek DC, et al: Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 76: 2753-2762, 2002.
30. Schweinitz A, Steinmetzer T, Banke IJ, et al: Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 279: 33613-33622, 2004.
31. Pulukuri SM, Gondi CS, Lakka SS, et al: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-36540, 2005.
32. Sabbisetti VS, Chigurupati S, Thomas S and Shah GV: Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion. Int J Cancer 118: 2694-2702, 2005.
33. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
34. Gondi CS, Lakka SS, Yanamandra N, et al: Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64: 4069-4077, 2004.
35. Yebra M, Goretzki L, Pfeifer M and Mueller BM: Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250: 231-240, 1999.
36. Langer DJ, Kuo A, Kariko K, et al: Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways. Circ Res 72: 330-340, 1993.
37. Miyake H, Hara I, Yamanaka K, Arakawa S and Kamidono S: Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14: 535-541, 1999.
38. Rabbani SA and Xing RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies (Review). Int J Oncol 12: 911-920, 1998.
39. Jo M, Thomas KS, O'Donnell DM and Gonias SL: Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 278: 1642-1646, 2003.